Hoth Therapeutics Advances Multi-Asset Pipeline with Phase 2 Progress and Orphan Drug Designation
核心洞察
Hoth Therapeutics reports strong safety profile for HT-001 in Phase 2 CLEER-001 trial targeting EGFR-inhibitor-associated rash (搜索) with no dose-limiting toxicities observed.
The company's HT-KIT program for mastocytosis (搜索) has received FDA Orphan Drug Designation and is progressing toward IND submission in 2026.
A newly launched GDNF (搜索)-based metabolic program targeting obesity (搜索) and hepatic steatosis (搜索) has initiated studies with the Atlanta VA Medical Center.
Hoth Therapeutics has provided a comprehensive update on its therapeutic pipeline, highlighting clinical progress across multiple programs including a Phase 2 trial showing favorable safety data and an orphan drug-designated asset advancing toward clinical development. The clinical-stage biopharmaceutical company detailed meaningful progress across four key programs while expanding its intellectual property portfolio and strategic research partnerships.
HT-001 Demonstrates Safety in Oncology Supportive Care
The company's lead asset HT-001, a topical epidermal growth factor inhibitor, continues to advance in its Phase 2 CLEER-001 clinical trial targeting EGFR-inhibitor-associated rash (搜索), addressing a significant unmet need in oncology supportive care. Recent progress includes a strong safety profile to date with no dose-limiting toxicities observed and consistent improvement trends in rash severity and pruritus. The trial has also seen increased clinical-site engagement and favorable investigator feedback, with a further clinical update anticipated in the coming months as enrollment continues to progress.
Orphan-Designated HT-KIT Approaches Clinical Development
HT-KIT, Hoth's targeted KIT (搜索)-inhibitor program for mastocytosis (搜索) and related mast-cell-driven diseases, has achieved several key milestones while progressing through IND-enabling activities. The program has already received FDA Orphan Drug Designation and demonstrated compelling preclinical efficacy showing potent KIT inhibition and suppressed mast-cell activation. IND-enabling toxicology studies are moving toward completion alongside ongoing manufacturing scale-up and analytical characterization. Hoth expects to finalize its IND submission in 2026, followed by first-in-human studies.
GDNF Program Targets Metabolic Dysfunction
The company's newest initiative leverages GDNF (搜索) (Glial-Derived Neurotrophic Factor) to target obesity (搜索), hepatic steatosis (搜索), and metabolic dysfunction, representing one of the largest and fastest-growing therapeutic markets globally. Study preparations have been initiated with the Atlanta VA Medical Center, with mouse procurement completed and high-fat-diet regimen launches per approved VA protocols. Aim 1 of the research program is now underway, with early data expected in 2026. The program is supported by strong academic collaboration and growing IP protection.
Alzheimer's Program Advances Through Development
HT-ALZ continues to deliver supportive data across absorption, distribution, and neuroinflammatory pathways for Alzheimer's disease (搜索) treatment. GLP studies are underway with positive PK, biodistribution, and CNS-penetration modeling, with the regulatory-facing package expected to mature in 2026.
Strategic Positioning and Future Milestones
Hoth continues to broaden its IP position through new filings and expanded protection around HT-001 dermatology and oncology-supportive-care mechanisms, HT-KIT mast-cell-disease formulations, HT-ALZ CNS-focused data and delivery systems, and GDNF (搜索) weight-loss and hepatic-function applications. The company maintains collaborations with leading institutions, including the Atlanta VA Medical Center, academic neuroscience groups, and AI-assisted discovery platforms.
Upcoming milestones include a CLEER-001 Phase 2 HT-001 clinical data update, completion of toxicology and IND filing for HT-KIT, GLP and pharmacokinetic updates for HT-ALZ, and early findings from the VA metabolic program.
"Our therapeutic pipeline has never been more focused or better positioned. With HT-001 advancing in the clinic, HT-KIT nearing IND submission, HT-ALZ progressing through GLP development, and our new GDNF (搜索) program targeting one of the largest markets in medicine," commented Robb Knie, Chief Executive Officer of Hoth Therapeutics.